Literature DB >> 14517509

Duration and morbidity of newly diagnosed idiopathic thrombocytopenic purpura in children: A prospective Nordic study of an unselected cohort.

Steen Rosthøj1, Iris Hedlund-Treutiger, Jukka Rajantie, Bernward Zeller, Olafur G Jonsson, Göran Elinder, Finn Wesenberg, Jan-Inge Henter.   

Abstract

OBJECTIVE: To determine the duration of the risk period with platelet counts <20 x 10(9)/L and the frequency of bleeding episodes in unselected children with idiopathic thrombocytopenic purpura (ITP). STUDY
DESIGN: We established a registry for patients with newly diagnosed ITP in the five Nordic countries, enrolling children aged 0 to 14 years with platelet counts <30 x 10(9)/L. Treatment centers prospectively reported presenting features, management details, and disease-related events during the first six months after diagnosis.
RESULTS: At presentation (n=501), more than half of the children had a platelet count <10 x 10(9)/L, but only 15 (3.0%) had a hemorrhage requiring blood transfusion. During follow-up of 409 patients, thrombocytopenia resolved uneventfully in 277. A risk period was present in 376 cases. Among 283 with self-limiting ITP, 26 were at risk >1 month and 25 had 30 events. Among 93 patients with chronic ITP, 73 were at risk >1 month and 44 had 111 events. Events occurred with an average frequency of 0.39 per month at risk. Life-threatening hemorrhages did not occur in the first six months after diagnosis.
CONCLUSION: Most children with ITP are at risk for serious bleeding for less than one month. Continuing severe thrombocytopenia is associated with little morbidity, bleeding episodes being infrequent and very rarely serious.

Entities:  

Mesh:

Year:  2003        PMID: 14517509     DOI: 10.1067/s0022-3476(03)00245-2

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  17 in total

1.  Recent advances in the treatment of chronic refractory immune thrombocytopenic purpura.

Authors:  Kiarash Kojouri; James N George
Journal:  Int J Hematol       Date:  2005-02       Impact factor: 2.490

2.  Does treatment of newly diagnosed idiopathic thrombocytopenic purpura reduce morbidity?

Authors:  Iris Treutiger; Jukka Rajantie; Bernward Zeller; Jan-Inge Henter; Göran Elinder; Steen Rosthøj
Journal:  Arch Dis Child       Date:  2007-04-25       Impact factor: 3.791

3.  Management of immune thrombocytopenic purpura: an update.

Authors:  Rajasekharan Warrier; Aman Chauhan
Journal:  Ochsner J       Date:  2012

4.  Misdiagnosed thrombocytopenia in children and adolescents: analysis of the Pediatric and Adult Registry on Chronic ITP.

Authors:  Alexandra Schifferli; Andrea Heiri; Paul Imbach; Susanne Holzhauer; Markus G Seidel; Diane Nugent; Marc Michel; Thomas Kühne
Journal:  Blood Adv       Date:  2021-03-23

5.  Recent trends in practice patterns and comparisons between immunoglobulin and corticosteroid in pediatric immune thrombocytopenia.

Authors:  Yusuke Okubo; Nobuaki Michihata; Naho Morisaki; Mayumi Hangai; Hiroki Matsui; Kiyohide Fushimi; Hideo Yasunaga
Journal:  Int J Hematol       Date:  2017-08-28       Impact factor: 2.490

6.  Transient and chronic childhood immune thrombocytopenia are distinctly affected by Fc-γ receptor polymorphisms.

Authors:  David E Schmidt; Katja M J Heitink-Pollé; Annemieke G Laarhoven; Marrie C A Bruin; Barbera Veldhuisen; Sietse Q Nagelkerke; Taco W Kuijpers; Leendert Porcelijn; C Ellen van der Schoot; Gestur Vidarsson; Masja de Haas
Journal:  Blood Adv       Date:  2019-07-09

Review 7.  The Use of Clinical Scores in the Management of Immune Thrombocytopenic Purpura in Children.

Authors:  Vasile Eduard Roşu; Elena-Lia Spoială; Tamara Solange Roşu; Anca-Viorica Ivanov; Adriana Mocanu; Alecsandra Munteanu; Vasile Valeriu Lupu; Ingrith Miron; Cristina Gavrilovici
Journal:  Front Pediatr       Date:  2022-05-09       Impact factor: 3.569

8.  Association between drug and vaccine use and acute immune thrombocytopenia in childhood: a case-control study in Italy.

Authors:  Federica Bertuola; Carla Morando; Francesca Menniti-Ippolito; Roberto Da Cas; Annalisa Capuano; Giorgio Perilongo; Liviana Da Dalt
Journal:  Drug Saf       Date:  2010-01-01       Impact factor: 5.606

9.  Management strategies for newly diagnosed immune thrombocytopenia in Italian AIEOP Centres: do we overtreat? Data from a multicentre, prospective cohort study.

Authors:  Emilia Parodi; Giovanna Russo; Piero Farruggia; Lucia D Notarangelo; Maria T Giraudo; Margherita Nardi; Fiorina Giona; Paola Giordano; Ugo Ramenghi; Angelica Barone; Gianluca Boscarol; Simone Cesaro; Francesca Fioredda; Saverio Ladogana; Maria Licciardello; Francesca Rossi; Laura Rubert; Marco Spinelli; Fabio Tucci
Journal:  Blood Transfus       Date:  2020-07-22       Impact factor: 3.443

10.  Childhood Immune Thrombocytopenia: Long-term Follow-up Data Evaluated by the Criteria of the International Working Group on Immune Thrombocytopenic Purpura.

Authors:  Melike Sezgin Evim; Birol Baytan; Adalet Meral Güneş
Journal:  Turk J Haematol       Date:  2014-03-05       Impact factor: 1.831

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.